PD-1单抗-话题@MedSci

#PD-1单抗#

77篇内容 | 2792人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用, objectType=article, longId=185777, objectId=0711185e771a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0711185e771a, replyNumber=0, likeNumber=51, createdTime=2020-01-07, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0711185e771a, moduleTitle=Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0711185e771a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364875, encodeId=c29513648e558, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=PD-1单抗单药治疗双原发癌，局部晚期肺鳞癌肿瘤疗效PR，肝细胞癌肿瘤疗效评估pCR, objectType=article, longId=184137, objectId=74cc18413e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cc18413e05, replyNumber=0, likeNumber=93, createdTime=2019-12-05, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cc18413e05, moduleTitle=PD-1单抗单药治疗双原发癌，局部晚期肺鳞癌肿瘤疗效PR，肝细胞癌肿瘤疗效评估pCR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74cc18413e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364874, encodeId=bf7113648e498, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, objectType=article, longId=184092, objectId=92cd1840921e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cd1840921e, replyNumber=0, likeNumber=54, createdTime=2019-12-05, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cd1840921e, moduleTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92cd1840921e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364873, encodeId=e2a813648e3d1, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=默克的PD-1单抗Keytruda获得国内非小细胞肺癌适应症的第三次批准, objectType=article, longId=184025, objectId=7f2c18402514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f2c18402514, replyNumber=0, likeNumber=90, createdTime=2019-12-04, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f2c18402514, moduleTitle=默克的PD-1单抗Keytruda获得国内非小细胞肺癌适应症的第三次批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f2c18402514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364872, encodeId=0ade13648e25b, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期, objectType=article, longId=184023, objectId=8e3e1840235e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3e1840235e, replyNumber=0, likeNumber=76, createdTime=2019-12-04, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3e1840235e, moduleTitle=默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e3e1840235e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364871, encodeId=2b8613648e11a, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=Inovio的INO-5401联合PD-1单抗cemiplimab治疗多形胶质母细胞瘤的2期研究，显示出80％的6个月无进展生存率, objectType=article, longId=182511, objectId=04741825119a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04741825119a, replyNumber=0, likeNumber=60, createdTime=2019-11-08, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04741825119a, moduleTitle=Inovio的INO-5401联合PD-1单抗cemiplimab治疗多形胶质母细胞瘤的2期研究，显示出80％的6个月无进展生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04741825119a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364870, encodeId=ad1713648e062, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=75, createdTime=2019-10-25, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364869, encodeId=725513648699e, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, objectType=article, longId=178992, objectId=cb1b1e899242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1b1e899242, replyNumber=0, likeNumber=41, createdTime=2019-09-07, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1b1e899242, moduleTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1b1e899242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364868, encodeId=e9fa1364868de, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=PD-1单抗Keytruda又一重大突破：与阿西替尼联合获欧盟批准用作晚期肾细胞癌（RCC）的一线治疗, objectType=article, longId=178980, objectId=52fd1e8980a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52fd1e8980a7, replyNumber=0, likeNumber=65, createdTime=2019-09-07, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52fd1e8980a7, moduleTitle=PD-1单抗Keytruda又一重大突破：与阿西替尼联合获欧盟批准用作晚期肾细胞癌（RCC）的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52fd1e8980a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364867, encodeId=c8a6136486ea9, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=晚期食管鳞癌一线PD-1单抗联合化疗获良效, objectType=article, longId=178525, objectId=35521e852530, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35521e852530, replyNumber=0, likeNumber=51, createdTime=2019-09-03, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35521e852530, moduleTitle=晚期食管鳞癌一线PD-1单抗联合化疗获良效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35521e852530)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364866, encodeId=54b9136486624, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=Oncologie宣布与Merck进行临床试验合作，评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌, objectType=article, longId=177568, objectId=24091e7568e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24091e7568e4, replyNumber=0, likeNumber=102, createdTime=2019-08-15, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24091e7568e4, moduleTitle=Oncologie宣布与Merck进行临床试验合作，评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24091e7568e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364865, encodeId=0e07136486540, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌, objectType=article, longId=174938, objectId=c1da1e4938eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e4938eb, replyNumber=0, likeNumber=67, createdTime=2019-07-08, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e4938eb, moduleTitle=英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e4938eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364864, encodeId=b706136486499, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=欧盟批准赛诺菲的PD-1单抗Libtayo用于治疗皮肤癌, objectType=article, longId=174726, objectId=564d1e472602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=564d1e472602, replyNumber=0, likeNumber=74, createdTime=2019-07-05, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=564d1e472602, moduleTitle=欧盟批准赛诺菲的PD-1单抗Libtayo用于治疗皮肤癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=564d1e472602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364863, encodeId=c46a13648636c, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景, objectType=article, longId=167676, objectId=769c16e676a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=769c16e676a7, replyNumber=0, likeNumber=69, createdTime=2019-06-06, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=769c16e676a7, moduleTitle=BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=769c16e676a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364862, encodeId=d5d41364862e2, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=第三个国产PD-1单抗正式获批, objectType=article, longId=167391, objectId=6ec716e39173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ec716e39173, replyNumber=0, likeNumber=59, createdTime=2019-06-02, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ec716e39173, moduleTitle=第三个国产PD-1单抗正式获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ec716e39173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364861, encodeId=6c7313648618b, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=PD-1单抗三线治疗转移性胃癌，推荐等级“更上一层楼”, objectType=article, longId=166820, objectId=65e916682030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e916682030, replyNumber=0, likeNumber=63, createdTime=2019-05-27, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e916682030, moduleTitle=PD-1单抗三线治疗转移性胃癌，推荐等级“更上一层楼”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65e916682030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364860, encodeId=7919136486036, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=CTLA4单抗ipilimumab和PD-1单抗nivolumab联合的临床研究证实：该药物组合对晚期肾细胞癌患有明显治疗优势, objectType=article, longId=166310, objectId=318316631011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=318316631011, replyNumber=0, likeNumber=0, createdTime=2019-05-20, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=318316631011, moduleTitle=CTLA4单抗ipilimumab和PD-1单抗nivolumab联合的临床研究证实：该药物组合对晚期肾细胞癌患有明显治疗优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=318316631011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364859, encodeId=6fc3136485962, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=ESMO Breast：三阴性乳腺癌患者的肿瘤浸润淋巴细胞水平与PD-1单抗keytruda应答率呈显著正相关, objectType=article, longId=165486, objectId=e8fc16548616, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8fc16548616, replyNumber=0, likeNumber=72, createdTime=2019-05-08, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8fc16548616, moduleTitle=ESMO Breast：三阴性乳腺癌患者的肿瘤浸润淋巴细胞水平与PD-1单抗keytruda应答率呈显著正相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8fc16548616)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364858, encodeId=149b13648585c, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=PD-1单抗Opdivo用作小细胞肺癌的维持免疫疗法，临床试验结果令人失望, objectType=article, longId=164164, objectId=4afe164164c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4afe164164c6, replyNumber=0, likeNumber=57, createdTime=2019-04-14, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4afe164164c6, moduleTitle=PD-1单抗Opdivo用作小细胞肺癌的维持免疫疗法，临床试验结果令人失望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4afe164164c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364857, encodeId=3d3d136485e82, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=默沙东的PD-1单抗Keytruda获FDA批准治疗新的非小细胞肺癌亚型, objectType=article, longId=164162, objectId=4d0c164162a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d0c164162a0, replyNumber=0, likeNumber=71, createdTime=2019-04-14, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d0c164162a0, moduleTitle=默沙东的PD-1单抗Keytruda获FDA批准治疗新的非小细胞肺癌亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d0c164162a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1单抗

2020-05-29

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用

2020-01-07

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

PD-1单抗单药治疗双原发癌，局部晚期肺鳞癌肿瘤疗效PR，肝细胞癌肿瘤疗效评估pCR

2019-12-05

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗

2019-12-05

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

默克的PD-1单抗Keytruda获得国内非小细胞肺癌适应症的第三次批准

2019-12-04

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期

2019-12-04

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

Inovio的INO-5401联合PD-1单抗cemiplimab治疗多形胶质母细胞瘤的2期研究，显示出80％的6个月无进展生存率

2019-11-08

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

2019-10-25

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

2019-09-07

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

PD-1单抗Keytruda又一重大突破：与阿西替尼联合获欧盟批准用作晚期肾细胞癌（RCC）的一线治疗

2019-09-07

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

晚期食管鳞癌一线PD-1单抗联合化疗获良效

2019-09-03

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

Oncologie宣布与Merck进行临床试验合作，评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌

2019-08-15

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌

2019-07-08

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

欧盟批准赛诺菲的PD-1单抗Libtayo用于治疗皮肤癌

2019-07-05

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景

2019-06-06

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

第三个国产PD-1单抗正式获批

2019-06-02

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

PD-1单抗三线治疗转移性胃癌，推荐等级“更上一层楼”

2019-05-27

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

CTLA4单抗ipilimumab和PD-1单抗nivolumab联合的临床研究证实：该药物组合对晚期肾细胞癌患有明显治疗优势

2019-05-20

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

ESMO Breast：三阴性乳腺癌患者的肿瘤浸润淋巴细胞水平与PD-1单抗keytruda应答率呈显著正相关

2019-05-08

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

PD-1单抗Opdivo用作小细胞肺癌的维持免疫疗法，临床试验结果令人失望

2019-04-14

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

默沙东的PD-1单抗Keytruda获FDA批准治疗新的非小细胞肺癌亚型

2019-04-14

科室
- - 订阅+
  - 更多科室
工具
服务